In three syngeneic tumor models, systemic treatment with the IRE1α inhibitor attenuated tumor growth more strongly than did IRE1α disruption selectively in the malignant cells, indicating that IRE1α activity in the TME supports tumor growth. The gene discussed is ERN1; the disease is neoplasm.